Cathie Wood Keeps Buying Gingko Bioworks (DNA) Stock
Investor Place · 2d ago
Tesla Bull Cathie Wood Scoops Up $11.5M In Bill Gates-Backed Biotech's Stock
Ark Investment Management, led by Tesla Inc.
Benzinga · 3d ago
Ginkgo Bioworks downgraded at BofA with price target cut to half
Ginkgo Bioworks (NYSE:DNA) is trading lower in the morning hours Wednesday after Bank of America downgraded the cell programming company to Underperform from Neutral and slashed its price target by
Seekingalpha · 4d ago
BofA Downgrades Ginkgo Bioworks, Cuts Price Target In Half
While Ginkgo Bioworks Holdings Inc’s (NYSE: DNA) overall first-quarter results were better than expected, revenues and active programs in its core Foundry segment fell short of estimates, according to BofA Securities.
Benzinga · 4d ago
Ginkgo Bioworks And First Serv Announce Plans To Develop And Implement Innovative Global Biosecurity Capabilities In Qatar
Partnership recognizes the importance of global cooperation to prevent and respond to pandemics By leveraging Ginkgo's large-scale biosecurity platform and Qatar's pioneering investments in
Benzinga · 4d ago
Ginkgo Bioworks and First Serv Announce Plans to Develop and Implement Innovative Global Biosecurity Capabilities in Qatar
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and First Serv, a Qatari investment holding company, today announced that they have entered into a non-binding Memorandum of Understanding (MOU) to develop and implement new...
PR Newswire · 4d ago
--BofA Securities Downgrades Ginkgo Bioworks Holdings to Underperform From Neutral, Adjusts Price Target to $3 From $6
MT Newswires · 5d ago
Ginkgo Bioworks, First Serv Sign MoU to Develop, Implement Global Biosecurity Capabilities in Qatar
MT Newswires · 5d ago
Mid-Afternoon Market Update: Crude Oil Down Over 1%; Jumia Technologies Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 200 points on Tuesday.
Benzinga · 5d ago
Ginkgo Bioworks sees quarterly net loss widen dramatically following jump in expenses
Q1 2022 net loss for Ginkgo Bioworks Holdings (NYSE:DNA) increased 692% to $590.5M compared to the prior-year period due to significant increases in R&D, and general and administrative expenses. Revenue
Seekingalpha · 6d ago
Ginkgo Bioworks Holdings Q1 EPS $(0.37) Down From $(0.06) YoY, Sales $168.41M Beat $105.68M Estimate
Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(0.37) per share. This is a 516.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales
Benzinga · 6d ago
Why Ginkgo Bioworks Stock Is Falling After Hours
Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading lower in Monday's after-hours session after the company 
Benzinga · 6d ago
Ginkgo Bioworks Holdings GAAP EPS of -$0.37 misses by $0.20, revenue of $168.4M beats by $62.73M
Ginkgo Bioworks Holdings press release (NYSE:DNA): Q1 GAAP EPS of -$0.37 misses by $0.20. Revenue of $168.4M (+281.9% Y/Y) beats by $62.73M. 11 new Cell Programs added in Q1 2022,
Seekingalpha · 6d ago
BRIEF-Ginkgo Bioworks Reports First Quarter 2022 Financial Results · 6d ago
Ginkgo Bioworks Q1 Loss Expands; Revenue Rises; Company Boosts 2022 Revenue Guidance
MT Newswires · 6d ago
-- Earnings Flash (DNA) GINKGO BIOWORKS Posts Q1 Revenue $168M
MT Newswires · 6d ago
Notable earnings after Monday's close
Seekingalpha · 05/15 21:35
Ginkgo Bioworks Holdings (NYSE:DNA) shareholders have endured a 73% loss from investing in the stock a year ago
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
Simply Wall St. · 05/14 13:59
Ginkgo Bioworks Holdings Q1 2022 Earnings Preview
Ginkgo Bioworks Holdings (NYSE:DNA) Q1 consensus EPS estimate is -$0.18 and consensus revenue estimate is $105.67M. DNA is scheduled to announce Q1 earnings results on Monday, May 16, after market close. Over the
Seekingalpha · 05/13 21:35
Looking Into Ginkgo Bioworks Holdings's Recent Short Interest
Ginkgo Bioworks Holdings's (NYSE:DNA) short percent of float has risen 9.65% since its last report. The company recently reported that it has 81.30 million shares sold short, which is 10.34% of all regular shares that are available for trading.
Benzinga · 05/13 19:02
Webull provides a variety of real-time DNA stock news. You can receive the latest news about Ginkgo Bioworks Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About DNA
Ginkgo Bioworks Holdings, Inc., formerly Spinning Eagle Acquisition Corp, is engaged in building a platform to program cells. The Company's platform is used to program cells on behalf of its customers. Its cell programs are designed to enable biological production of products as therapeutics, key food ingredients, and chemicals derived from petroleum. The Company's platform is used to design, write, and debug deoxyribonucleic acid (DNA) code in engineered organisms to execute programs for its customers. Its platform is used by customers for manufacturing processes or develop new products through biology. The foundation of its platform includes two assets that execute a variety of cell programs for customers according to their specifications: Foundry and Codebase. It serves industries, including chemicals, agriculture, food, consumer products and pharmaceuticals.